Source link : https://www.newshealth.biz/health-news/fda-reviewers-skeptical-of-ocaliva-for-rare-bile-duct-disease/
FDA advisors on Friday will be asked to find any clinical benefit in the rocky, mostly-null evidence for obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC). In its present supplemental new drug application, sponsor Intercept Pharmaceuticals is proposing an indication for obeticholic acid to reduce hepatic decompensation, liver transplant, and death in adults with PBC […]
Author : News Health
Publish date : 2024-09-11 18:16:27
Copyright for syndicated content belongs to the linked Source.